Evidence map›Paper›PMID 33647448›Full record

ArticleCellular signalling2021

Chemotherapy-induced acute vascular injury involves intracellular generation of ROS via activation of the acid sphingomyelinase pathway.

Aviram Mizrachi, Irit Ben-Aharon, Hongyan Li, Hadas Bar-Joseph, Chloe Bodden, Elad Hikri, Aron Popovtzer, Ruth Shalgi, Adriana Haimovitz-Friedman

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Aviram MizrachiHead and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Otorhinolaryngology Head and Neck Surgery and Center for Translational Research in Head and Neck Cancer, Rabin Medical Center, Petah Tikva, Israel.
Irit Ben-AharonDivision of Oncology, Rambam Health Care Campus, Haifa, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hongyan LiDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Hadas Bar-JosephSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Chloe BoddenDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Elad HikriSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Otorhinolaryngology Head and Neck Surgery and Center for Translational Research in Head and Neck Cancer, Rabin Medical Center, Petah Tikva, Israel.
Aron PopovtzerDivision of Oncology, Rambam Health Care Campus, Haifa, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Otorhinolaryngology Head and Neck Surgery and Center for Translational Research in Head and Neck Cancer, Rabin Medical Center, Petah Tikva, Israel.
Ruth ShalgiSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Adriana Haimovitz-FriedmanDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: haimovitz-friedman@ski.mskcc.org.
Tel Aviv University · ILMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Ceramide synthase as a therapy target in prostate cancerR01CA105125 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HAIMOVITZ-FRIEDMAN, ADRIANA · 2005 to 2009
$1.6M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA105125
6 · The paper itself

Abstract

Several categories of chemotherapy confer substantial risk for late-term vascular morbidity and mortality. In the present study, we aimed to investigate the mechanism of acute chemotherapy-induced vascular injury in normal tissues. Specifically, we looked at activation of the acid sphingomyelinase (ASMase)/ceramide pathway, which leads to generation of reactive oxygen species (ROS) and induction of oxidative stress that may result in vascular injury. In particular, we focused on two distinct drugs, doxorubicin (DOX) and cisplatin (CIS) and their effects on normal endothelial cells. In vitro, DOX resulted in increased ASMase activity, intra-cellular ROS production and induction of apoptosis. CIS treatment generated significantly reduced effects in endothelial cells. In-vivo, murine femoral arterial blood flow was measured in real-time, during and after DOX or CIS administration, using fluorescence optical imaging system. While DOX caused constriction of small vessels and disintegration of large vessels' wall, CIS induced minor vascular changes in arterial blood flow, correlating with the in vitro findings. These results demonstrate that DOX induces acute vascular injury by increased ROS production, via activation of ASMase/ceramide pathway, while CIS increases ROS production and its immediate extracellular translocation, without causing detectable acute vascular injury. Our findings may potentially lead to the development of new strategies to prevent long-term cardiovascular morbidity in cancer survivors.

Indexed as

AnimalsAntineoplastic AgentsCattleCell LineCisplatinDoxorubicinEndothelial CellsMiceOxidative StressReactive Oxygen SpeciesVascular System InjuriesAntineoplastic AgentsCisplatinDoxorubicinReactive Oxygen SpeciesAcid sphingomyelinaseCisplatinDoxorubicinNormal tissuesVascular injury

Identifiers

PMID33647448
PMCPMC10402763
OpenAlexW3134172426

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.